Tumor Immunology and Tumor Immunotherapy

  • HI-TRON Mainz
  • Immunology, Infection and Cancer
Portrait von Prof. Dr. Niels Halama, Leiter der Abteilung Tumorimmunologie und Tumorimmuntherapie

Prof. Dr. Niels Halama

Integration of broad aspects of immunological parameters for the successful development and optimization of therapeutic approaches in clinical translation.

Our Research

Tertiary lymphoid structures

Cancer immunology has moved from scientific insight into practice changing standards in oncology. Robust scientific evidence has provided the entry to successful clinical translation. The department of translational immunotherapy is integrating broad aspects of immunological parameters (i.e. tissue-specific regulation, microbiome, metabolic regulation, genomic factors etc.) for the successful development and optimization of therapeutic approaches in clinical translation. An important part is to better understand the regulation of immune responses within tissues of solid tumors. Dedicated biomarker research for the identification of relevant immune cell phenotypes is also a decisive factor like understanding the cytokine regulatory network in specific disease situations. Deeper insights into the situation in human patients are provided by our fully-human preclinical Explant Model System, which is able to recapitulate the microenvironment of individual patients. In addition, new computational model systems, databases and machine learning (“artificial intelligence”) allow to further elaborate our understanding of the regulation of immune responses. Especially our explant model systems open new possibilities in development of new therapies. Newly developed therapies have been successfully translated into the clinic and combinatorial immunomodulation based on adaptive clinical trial protocols with biomarker driven selection programs are now being implemented.

Cancer immunotherapy has revolutionized oncology. As a standard of care for some cancer entities, broad application in the treatment of patients with hematologic and solid tumors has become a reality. Identification of patients for a specific immunomodulatory approach, identification of successful combinatorial immunotherapy (or combination with chemotherapy, radiation or other intervention) are all important next steps to be developed also together in the Helmholtz Institute for Translational Oncology (HITRON). Utilizing new model systems and informative trial designs, the connection of basic research and translational efforts make this area highly diverse and challenging, but show the potential for a future of personalized therapy in oncology.

Projects

The longstanding expertise in connecting insights from pre-clinical model systems with early clinical trials revealed multiple possible interventions and early clinical trials. Two examples for this systematic approach and successful translation encompass the modulation of the chemokine axis CCL5 and its receptor CCR5 (Halama N et al, 2016, Cancer Cell) as well as the inhibition of the cytokine SDF1alpha. Systematic analyses of the microenvironment utilizing the explant model system (Halama N et al, 2016, Cancer Cell) indicated possible synergies for classical checkpoint blockade combined with inhibition of CCR5. The corresponding trial (PICASSO, ClinicalTrials.gov Identifier: NCT03274804) was performed with concomitant serial biopsies, allowing to investigate the effects of anti-PD-1 (Pembrolizumab) and CCR5 inhibition in massively pre-treated colorectal cancer patients. Although the findings from the PICASSO trial are published, the parallel trial investigating the triple immunotherapy combination treatment (LUMINESCENCE, ClinicalTrials.gov Identifier: NCT04721301, PI Niels Halama) is still ongoing with 50 patients recruited (25 colorectal cancer and 25 pancreatic cancer, all microsatellite-stable). Combination of double checkpoint inhibitors (anti-PD-1, anti-CTLA4) with CCR5 inhibition showed promising synergistic effects, enhancing the anti-tumoral effect of macrophage re-polarization with enhanced activation of the adaptive arm of the immune system. Systematic analyses of serial biopsies and the microbiome in patients on trial show promising results, especially as there are ~20% of patients with disease control, making this sample set unique in an otherwise immunotherapy-unresponsive entity. Clinical follow-up and concomitant research are still ongoing. Another component of the tumor microenvironment is formed by fibroblasts, building a barrier for T cell infiltration and modulating the immune responses. Inhibition of the SDF1alpha has been reported to affect the tumor microenvironment via modulation of fibroblasts. The new approach of inhibiting specific cytokines through a RNA molecule (“spiegelmer technology”) was applied within the OPERA trial (KEYNOTE-559, ClinicalTrials.gov Identifier: NCT03168139, PI Niels Halama) and results were published in the Journal of Immunotherapy of Cancer. Here, the mode-of-action could be clarified and showed an activation of the adaptive immune system in a subset of patients with a specific myeloid cell population presumably being the drivers for the enhanced anti-tumoral effects. 


 [AM1]Format intext citaton: (Mustermann D et al, year, Journal abbreviation, page)

 [HN2]Yes


 [AM1]Könnte man diese Referenzen zu den Datensätzen genauer spezifizieren, z.B. über eine Publikation?

 [HN2]Ja

 [AM3]Auch hier sollte weitestgehend das Format der in text citation genutzt werden.

 [HN4]Eingefügt


 [AM1]Format intext citaton: (Mustermann D et al, year, Journal abbreviation, page)

 [HN2]Yes

Team

A 14-person team consisting of biologists, molecular biologists and physicians is working on the development and optimization of new therapeutic approaches to successfully combat cancer.

14 Employees

  • Portrait von Prof. Dr. Niels Halama, Leiter der Abteilung Tumorimmunologie und Tumorimmuntherapie

    Prof. Dr. Niels Halama

    Show profile
    Contact form: Message to Prof. Dr. Niels Halama

    Form data is loaded ...

  • Dr. Azaz Ahmed

    Contact form: Message to Dr. Azaz Ahmed

    Form data is loaded ...

  • Portrait von Anna Berthel

    Dr. Anna Berthel

    Contact form: Message to Dr. Anna Berthel

    Form data is loaded ...

  • Portrait von Marion Drechsel

    Marion Drechsel

    Contact form: Message to Marion Drechsel

    Form data is loaded ...

  • Dr. Silke Grauling-Halama

    Contact form: Message to Dr. Silke Grauling-Halama

    Form data is loaded ...

  • Portrait von Florian Heininger

    Florian Heininger

    Contact form: Message to Florian Heininger

    Form data is loaded ...

  • Portrait von Alicia Höflich

    Alicia Höflich

    Contact form: Message to Alicia Höflich

    Form data is loaded ...

  • Portrait von Xu Holtkotte

    Dr. Xu Holtkotte

    Contact form: Message to Dr. Xu Holtkotte

    Form data is loaded ...

  • Portrait von Karla Kerekovic

    Karla Kerekovic

    Contact form: Message to Karla Kerekovic

    Form data is loaded ...

  • Alexandra Pöchmann

    Contact form: Message to Alexandra Pöchmann

    Form data is loaded ...

  • Dr. Meggy Suarez-Carmona

    Contact form: Message to Dr. Meggy Suarez-Carmona

    Form data is loaded ...

  • Portrait von Silke Will

    Silke Will

    Contact form: Message to Silke Will

    Form data is loaded ...

  • Jana Wolf

    Contact form: Message to Jana Wolf

    Form data is loaded ...

  • Xin-Wen Zhang

    Contact form: Message to Xin-Wen Zhang

    Form data is loaded ...

Selected publications

2023 - Cancers (Basel)
2016 - Cancer Cell

Get in touch with us

Two scientists looking at a computer monitor
Prof. Dr. Niels Halama
Abteilungsleiter
Contact form: Message to Prof. Dr. Niels Halama

Form data is loaded ...

Postal address:

Tumorimmunologie und Tumorimmuntherapie (D196) Deutsches Krebsforschungszentrum Obere Zahlbacher Str. 63 55131 Mainz
Two scientists looking at a computer monitor
Marion Drechsel
Office Manager
Contact form: Message to Marion Drechsel

Form data is loaded ...

Postal address:

Tumorimmunologie und Tumorimmuntherapie (D196) Deutsches Krebsforschungszentrum Obere Zahlbacher Str. 63 55131 Mainz